Table 1.
Baseline characteristics of patients with reference to PCC administration
| Overall series | Propensity score–matched pairs | |||||||
|---|---|---|---|---|---|---|---|---|
| No PCC (n = 680) | PCC (n = 291) | p Value | Pre-match SD | No PCC (n = 225) | PCC (n = 225) | p Value | Post-match SD | |
| Age, yr | 69.8 ± 10.1 | 69.0 ± 12.3 | 0.963 | 0.006 | 69.7 ± 10.6 | 69.2 ± 11.6 | 0.932 | 0.004 |
| Female sex | 263 (38.7) | 114 (39.2) | 0.884 | 0.01 | 91 (40.4) | 91 (40.4) | 1.000 | 0 |
| BMI, kg/m2 | 25.0 ± 4.5 | 25.4 ± 4.8 | 0.258 | 0.019 | 25.4 ± 4.9 | 25.0 ± 4.7 | 0.400 | 0.017 |
| eGFR, ml/min/1.73 m2 | 61 ± 21 | 66 ± 26 | 0.003 | 0.009 | 64 ± 23 | 64 ± 26 | 0.878 | 0.001 |
| Dialysis | 14 (2.1) | 7 (2.4) | 0.734 | 0.02 | 3 (1.3) | 6 (2.7) | 0.503 | 0.1 |
| Haematocrit, % | 38 ± 6 | 37 ± 5 | 0.047 | 0.026 | 36 ± 6 | 37 ± 5 | 0.206 | 0.019 |
| Haemoglobin, g/dl | 12.4 ± 2.0 | 12.1 ± 1.9 | 0.002 | 0.075 | 11.8 ± 2.0 | 12.1 ± 1.9 | 0.128 | 0.085 |
| Platelets, 109/L | 210 ± 83 | 213 ± 79 | 0.552 | 0 | 216 ± 88 | 209 ± 74 | 0.418 | 0 |
| Aspirin | 279 (39.9) | 69 (23.7) | <0.0001 | 0.353 | 60 (26.7) | 60 (26.7) | 1.000 | 0 |
| Clopidogrel | 64 (9.4) | 28 (9.6) | 0.918 | 0.007 | 22 (9.8) | 22 (9.8) | 1.000 | 0 |
| Warfarin | 94 (13.8) | 24 (8.2) | 0.015 | 0.18 | 24 (10.7) | 21 (9.3) | 0.637 | 0.047 |
| NYHA class III-IV | 94 (13.8) | 74 (25.4) | <0.0001 | 0.295 | 42 (18.7) | 44 (19.6) | 0.810 | 0.023 |
| Atrial fibrillation | 145 (21.3) | 62 (21.3) | 0.995 | 0 | 49 (21.8) | 50 (22.2) | 0.909 | 0.01 |
| Hypertension | 379 (55.7) | 194 (66.7) | 0.002 | 0.227 | 143 (53.6) | 142 (63.1) | 0.922 | 0.194 |
| Diabetes | 152 (22.4) | 42 (14.4) | 0.005 | 0.208 | 37 (16.4) | 36 (16.0) | 0.898 | 0.011 |
| Pulmonary disease | 86 (12.6) | 40 (13.7) | 0.641 | 0.033 | 34 (15.1) | 28 (12.4) | 0.412 | 0.078 |
| Dyslipidaemia | 200 (29.4) | 123 (42.3) | <0.0001 | 0.271 | 85 (37.8) | 83 (36.9) | 0.845 | 0.019 |
| Peripheral vascular disease | 110 (16.2) | 59 (20.3) | 0.123 | 0.106 | 38 (16.9) | 38 (16.9) | 1.000 | 0 |
| Cerebrovascular disease | 63 (9.3) | 48 (16.5) | 0.001 | 0.216 | 26 (11.6) | 30 (13.3) | 0.568 | 0.052 |
| Prior cardiac surgery | 91 (13.4) | 46 (15.8) | 0.320 | 0.068 | 37 (16.4) | 34 (15.1) | 0.698 | 0.036 |
| Myocardial infarction | 185 (27.2) | 48 (16.5) | <0.0001 | 0.261 | 43 (19.1) | 41 (18.2) | 0.809 | 0.023 |
| LVEF, % | 52 ± 13 | 53 ± 11 | 0.106 | 0.01 | 53 ± 12 | 52 ± 11 | 0.796 | 0.002 |
| Emergency | 161 (23.7) | 49 (16.8) | 0.018 | 0.172 | 45 (20.0) | 41 (18.2) | 0.632 | 0.046 |
| Pre-operative IABP | 36 (5.3) | 14 (4.8) | 0.755 | 0.023 | 14 (6.2) | 9 (4.0) | 0.284 | 0.1 |
BMI body mass index, eGFR estimated glomerular filtration rate, IABP intra-aortic balloon pump, LVEF left ventricular ejection fraction, NYHA New York Heart Association, PCC prothrombin complex concentrates, SD standard deviation
Continuous variables are reported as mean and standard deviation; nominal variables are reported as counts (percentages)